Cold Spring Harbor, N.Y. – Scientists at Cold Spring Harbor Laboratory have identified a candidate drug target for treating acute myeloid leukemia (AML), a white blood cell cancer that proliferates out of control in the bone marrow. The team, led by Assistant Professor Chris Vakoc, M.D., Ph.D., shows that blocking a protein called PRC2 halts this uncontrolled proliferation in the bone marrow of mice with AML.
PRC2, short for Polycomb Repression Complex 2, is a chromatin regulator – a type of protein that alters the way genes are expressed. PRC2 works by chemically modifying histones, which are proteins that associate intimately with DNA to regulate how it functions in the cell. The team has found that blocking PRC2 leads to the reactivation of a powerful anti-tumor pathway that can protect against AML. "Our results emphasize the idea that targeting chromatin regulators is an effective means of reawakening growth-halting mechanisms that lie dormant in most cancer cells," says Vakoc. The study appears online in Oncogene on April 2.
AML is caused by changes not only in the genome but also the epigenome, which can be likened to a chemical instruction manual that contains reversible or rewritable instructions on how genes are expressed in cells. "If you think of the genome as something that's hardwired, then the epigenome is something that can be rewired," explains Vakoc. A growing body of evidence suggests that AML can arise from dysregulation of the epigenetic machinery that controls chromatin.
Using an RNA interference (RNAi) screen in which small hairpin-shaped RNA were used to systematically switch off every known chromatin regulator, Vakoc's team, in collaboration with the lab of CSHL Adjunct Professor Scott Lowe, Ph.D., looked for signs of inhibition of the growth of leukemic cells but not normal cells. The team's previous use of this approach identified a potent target called Brd4, a drug for which is currently in pharmaceutical development. Much of the technology for RNAi screening has been pioneered at CSHL by the laboratory of Gregory Hannon, Ph.D.
"In our new screen, PRC2 was one of the few chromatin regulators that was needed by cancer cells, but dispensable for normal blood cells," says team member Eric Wang. Blocking PRC2 led to growth arrest of leukemic cells and their differentiation -- the loss of ability to self-renew.
Although the screen also turned up other potential drug targets when performed in vitro, i.e., in cells grown in the lab, PRC2 was one of the few targets whose inhibition stopped the growth of leukemic cells in the bone marrows of mice with an aggressive form of AML. "These advanced mouse models, pioneered by former CSHL post-doctoral fellow Johannes Zuber while he was in Scott Lowe's laboratory, have give us the ability to discriminate between unsuccessful targets that only work in plastic dishes and those that are effective inside animals," says Vakoc. The lack of such preclinical evaluation and validation is one reason why so many drug trials fail. The use of cancer mouse models as preclinical test-beds, as described in the current study, is a cornerstone of CSHL's Cancer Therapeutics Initiative, which guides drug development by prioritizing drug targets that are identified by RNAi screens.
"We found that targeting the PRC2 complex allows reactivation of Ink4/Arf, genes that control a powerful potent tumor suppressor pathway that becomes silenced in AML. This provides a clear rationale for a chromatin regulator as a drug target in this disease," says graduate student Junwei Shi, who performed these experiments.
Both cancer-causing oncogenes as well as tumor suppressor genes, which are frequently missing or inactivated in AML, are often challenging to target with small molecule inhibitors. "Epigenetic regulators such as PRC2, on the other hand, are considered druggable and therefore are good surrogate targets," explains Vakoc. "Targeting Brd4, for example, is a great way to switch off the Myc oncogene. And as this study shows, targeting PRC2 is a great way of switching on the Ink4/Arf tumor suppressors."
The druggability of PRC2 lies in its identity as a lysine methyltransferase, a type of protein with deep greasy pockets in its structure that are accessible to small molecule drugs that can block its activity. Lysine methyltransferase inhibitors are already being developed as candidate anticancer drugs by many pharmaceutical companies.
The work was funded by support from the Don Monti Memorial Foundation, the Laurie Strauss Leukemia Foundation, the Sass Foundation, the Edward P. Evans Foundation and the FM Kirby Foundation.
"The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia," appears online on April 2. The full citation is: J Shi, E Wang, J Zuber, A Rappaport, M Taylor, C Johns, SW Lowe and CR Vakoc.About Cold Spring Harbor Laboratory
Hema Bashyam | EurekAlert!
Further reports about: > CSHL > Gates Foundation > PRC2 > RNA > RNAi > Vakoc > acute myeloid leukemia > blood cell > bone marrow > cancer cells > cancer drug > cold fusion > drug trial > genetic regulator > mouse model > myeloid leukemia > polycomb > spring > tumor suppressor > tumor suppressor gene
Rainbow colors reveal cell history: Uncovering β-cell heterogeneity
22.09.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden
The pyrenoid is a carbon-fixing liquid droplet
22.09.2017 | Max-Planck-Institut für Biochemie
Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.
A warming planet
Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.
The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...
Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
22.09.2017 | Life Sciences
22.09.2017 | Medical Engineering
22.09.2017 | Physics and Astronomy